




"CML-CAB NEWS" - 4th edition

April 2021

EXECUTIVE SUMMARY OF LAST CML-CAB WITH NOVARTIS NOW AVAILABLE



On 18 February 2021 we held our 12th **CML Community Advisory Board (CML-CAB)** and 22nd CML-CAB session.

It was the 9th CML-CAB meeting with Novartis. Besides 9 company representatives mainly from the areas of Patient Engagement, Medical Affairs, Global Development, and Market Access, a multi-centennial body of experience consisting of 13 CML-CAB members and covering 241 patient or advocacy years attended this meeting. **CML-CAB members** selected to attend this specific meeting were chosen out of the total group of 19 CML-CAB members (with a total of near to 340 patient or advocacy years), based on expertise on the meeting topics.

The main objectives of this first CML-CAB in 2021 which took place in a virtual format and whose focus was on "Future Treatments and Current Access" were to foster a mutual understanding and to take tangible actions forward for Novartis, the patient community and both in collaboration. Main focus of the meeting was asciminib (ABL001) – Novartis' novel investigational treatment that specifically targets the ABL myristoyl pocket (STAMP). Topics discussed during the meeting included the Asciminib Development Program (incl. Patient Reported Outcomes measures and Quality of Life), its value proposition and positioning of the drug, as well as Novartis' global access strategy for asciminib.

Please click here to access the **full Executive Summary of this 12th CML-CAB meeting**.

A big THANK YOU to participants on both sides for engaged discussions and for taking time out of everyone's busy schedule in preparing and attending this CML-CAB meeting.

SLIDES AND RECORDINGS OF CML-CAB TRAINING SESSION ON "ACCESS TO CANCER TREATMENT IN LMIC" AND "VALUE PROPOSITION" NOW AVAILABLE



On 29 January 2021 we held a Training Session for all CML-CAB members in preparation for the CML-CAB with Novartis on 18 February 2021.

We thought the content of this training session could be of value to others too, and therefore decided to **publish the presentation slides and the respective recordings**.

The following topics have been converted into enduring content.


- **Access to Cancer Treatment in LMIC** - Pat Garcia-Gonzalez, CML-CAB co-chair and CEO The Max Foundation (USA) - **RECORDING - PRESENTATION SLIDES**
- **How do we measure value? Different models and challenges in pricing** - Zack Pemberton-Whiteley, CML-CAB member and CEO Leukaemia Care (UK) - **RECORDING - PRESENTATION SLIDES**
- **How to influence reimbursement decisions as a patient advocates?** - Zack Pemberton-Whiteley, CML-CAB member and CEO Leukaemia Care (UK) - **RECORDING - PRESENTATION SLIDES**



Thank you to our two fantastic speakers for giving these presentations and sharing their knowledge, and also for allowing us to make them public. We hope that you will find these capacity building materials useful!

CML-CAB SUCCESS STORY: TASIGNA FOR IRAQ

CML-CAB aims at achieving concrete results rather than just vague platitudes. Here is a recent example of what CML-CAB has achieved: after a year of negotiations between the CML Advocates Network, specifically CML-CAB, and Novartis, in February 2021 a first shipment of Tasigna covering 5 months of product arrived in Iraq, and a second one with 7 months of product followed in March.



We wish to take the opportunity to thank all members of the CML Advocates Network and CML-CAB involved in the process for their great work and engagement, and of course to Novartis for reacting to our pledge!



Smiling faces - Relieved Iraqi patients after having been handed over their treatment.

Access issues in your country with any TKI? We are always eager to understand about access issues. As a result of CML-CAB meetings, a follow-up mechanism has been put in place with several of our pharmaceutical partners. Please engage and share your experiences! If you have specific access issues with any TKI, please reach out to us by sending an e-mail to Nicole at nicole@cmladvocates.net. We will be more than happy to incorporate these in our follow-up with the companies.



Copyright © 2020 - All rights reserved.

Our mailing address is:
info@cmladvocates.net

Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).

